Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Supernus Pharmaceuticals ( (SUPN) ) just unveiled an announcement.
On April 1, 2026, Supernus Pharmaceuticals entered into an asset purchase agreement with Navitor Pharmaceuticals and its parent to acquire all rights, title, and interest in assets related to the compound NV-5138, or SPN-820, including intellectual property, inventory, regulatory materials, data, and associated contract rights and goodwill. The purchase price is structured around Supernus’s obligation to complete one Phase 2b study and potential milestone payments of up to $350 million tied to development, regulatory, and commercial achievements, with the company reserving the right to cease further development and milestone pursuit if the Phase 2 study is deemed unsuccessful.
The agreement includes customary representations, warranties, covenants, and indemnification provisions, allowing Supernus to offset or recover indemnification losses against milestone payments, and imposes a five-year post-closing non-compete and non-solicitation covenant on the restricted parties, reinforcing Supernus’s exclusive control over the compound’s future development and commercialization prospects.
The most recent analyst rating on (SUPN) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Neutral.
The score is held back primarily by weaker recent financial performance (2025 GAAP loss and lower free cash flow) and unattractive GAAP-based valuation (negative P/E). These are partially offset by improving technical momentum and a generally positive earnings-call outlook with strong 2026 revenue guidance, though execution and cost pressures keep the rating moderate.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies, with a particular emphasis on central nervous system disorders. Its pipeline includes product candidates such as NV-5138, also known as SPN-820, which targets neurological and psychiatric indications and is progressing through mid-stage clinical development.
Average Trading Volume: 740,012
Technical Sentiment Signal: Buy
Current Market Cap: $2.91B
See more data about SUPN stock on TipRanks’ Stock Analysis page.